AI-generated from publicly available materials.The US Treasury's recent proposal to limit investments in Chinese biotech could significantly impact future drug development collaborations.
China has become a pivotal source for drug candidates, but the US Treasury's new measures aim to restrict licensing agreements with Chinese firms. This initiative is part of an update to the Outbound Investment Security Programme (OISP), which seeks to limit US investments in advanced technologies in nations deemed "countries of concern," including China, Russia, and North Korea. Initially focused on sectors like semiconductors and AI, the OISP now encompasses biotechnology.
With estimates suggesting that approximately one-third of new drugs globally originate from Chinese research, the proposed regulations would impose restrictions on various technologies crucial for drug development. These include cell and gene therapies, drug delivery systems, and advanced biomanufacturing tools. This shift comes in tandem with legislative efforts, such as the Biotech Investment National Security Act (BINSA), aimed at scrutinizing outbound investments in biopharma, particularly those involving Chinese clinical trial sites with military ties.
In response to these proposed regulations, industry representatives have voiced strong opposition, labeling them as government overreach that could jeopardize US competitiveness in the biotech sector. As BIO's president, John Crowley, pointed out, an overly broad approach might deter innovation and investment, ultimately undermining the US's position in the global biotech landscape. The ongoing debate highlights the tension between national security concerns and the need for continued collaboration in drug development.